Navigation Links
Mylan Wins Its Amlodipine Case With Pfizer

PITTSBURGH, Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Court of Appeals for the Federal Circuit today granted its motion for a reversal of the district court judgment in its patent infringement litigation with Pfizer concerning amlodipine besylate.

On February 22, 2007, the district court for the Western District of Pennsylvania had ruled in favor of Pfizer and Mylan immediately appealed and has continued to fully expect a reversal of the decision. Mylan was able to launch its amlodipine products following a March 22, 2007 decision by the U.S. Court of Appeals for the Federal Circuit that claims 1-3 of the amlodipine '303 patent were invalid.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented: "We are pleased to have prevailed in our amlodipine besylate litigation and the judicial system ultimately confirmed the position that we were the first to assert and have consistently maintained concerning this product for over four years. We are further pleased that our first to market generic amlodipine products have saved patients, corporations, the government and taxpayers hundreds of millions of dollars in healthcare costs."

Amlodipine Besylate Tablets are the generic version of Pfizer's Norvasc(R) Tablets, which had U.S. sales of approximately $2.7 billion for the 12-month period ending Dec. 31, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.


'"/>




Page: 1

Related medicine news :

1. Mylan Announces Final FDA Approval for Fluoxetine Capsules
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Pfizer unveils anti-smoking drug
4. The Effectiveness Of The Breast Cancer Drug By Pfizer
5. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
6. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
7. Pfizer’s Eraxis Approved By The FD
8. Pfizer Launches Viagra For Lung Disease In UK
9. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
10. Pfizer Commences Its Advertising for Celebrex with All the Warnings
11. FDA Approves Pfizer’s Anti-smoking Dru
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: